Sanofi SEC Filings June 2026

Sanofi has published three press releases in June 2026. The first, dated June 4, announces the launch of Sanofi's 2026 global employee stock purchase plan, "Action 2026," open to approximately 75,000 employees in 52 countries. This plan, in its 12th year, aims to involve employees in the company's growth, with a subscription price offering a 20% discount and free matching shares. The second release, dated June 8, reports the European Commission's approval of Sanofi's Sarclisa subcutaneous formulation for multiple myeloma treatment. This marks the first anticancer therapy in the EU administered via an on-body injector, offering increased flexibility for patients. The third release, dated June 10, provides an update on the MOBILIZE phase 3 study of riliprubart for chronic inflammatory demyelinating polyneuropathy (CIDP). The study will be stopped due to an interim analysis indicating the study is unlikely to provide sufficient efficacy, though no safety concerns were identified. The financial impact of this discontinuation is expected to be minimal, with no change to the 2026 financial guidance.